Summary

Overview
Global Organ Care Systems (OCS) Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.
The Organ Care System (OCS) is a medical device to maintain donor organs for longer periods before transplant. It mimics human physiology and maintains organs in a similar environment and temperature to the human body. This method offers longer preservation than static cold storage, which can cause cold ischemia.
Market Dynamics: Drivers and Restraints
Rise in the technological advancements in systems
Technological advancements in organ care products are expected to boost market demand, offering reliability, ease, and convenience to professionals performing organ transplants. Product design, functionality, and features will influence adoption rates.
For instance, Organ-perfusion systems, such as "heart in a box" and ex vivo lung perfusion, have significantly impacted organ transplants. A heart in a box is a portable device that resuscitates a stopped heart, allowing for long-distance transplantation. This system doubles the time needed for heart transplantation from four hours to eight hours. Ex vivo lung perfusion preserves the donated lung in a machine outside the body, allowing it to be restored to a suitable transplant condition.
Furthermore, the Organ Care Systems (OCS) market is also driven by various other factors like rising incidence of organ failures, rising organ transplantations and others that help the market to grow during the forecast period.
Market Dynamics: Restraint
The market growth of Organ Care Systems (OCS) is hindered by the high cost of systems which for example DCD (circulatory-determined death) heart transplantation has shown comparable 30-day and 1-year survival rates to brain stem-determined death heart transplantation, regardless of the NRP or direct procurement and perfusion technique used.
This could lead to increased heart transplant activity and reduced waiting times, potentially reducing waiting list mortality and the need for implantable left ventricular assist device support. However, cost is a major constraint, as procurement of DCD hearts is complex and resource-intensive, with the TransMedics Organ Care System costing around $40000 per use.
Segment Analysis
The global organ care systems (OCS) market is segmented based on product type, organ type, end-user and region.
The portable from the product type segment accounted for approximately 51.7% of the organ care systems (OCS) market share
The portable from the product type segment accounted for approximately 51.7% and is expected to dominate during the forecast period. Portable Organ Care Systems (OCS) are devices designed to preserve and assess donor organs outside the body, mimicking human physiology and minimizing ischemia. These systems can be used for various organs, such as lungs, hearts, and livers.
For instance, on February 21, 2021, Great Ormond Street Hospital (GOSH) and Royal Papworth Hospital (RPH) collaborated to introduce a world-first paediatric heart transplant technique that has successfully expanded the donor pool and increased the number of transplants for eligible children in the UK by 50%.
The donation after circulatory death (DCD) heart transplant programme was previously only available to adults. For the first time, using a portable organ perfusion system called the TransMedics heart Organ Care System (OCS), the technique has now been made available for children, paving the way for six life-saving heart transplants for young patients at GOSH in 2020.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to the factors like high awareness and increasing number of organ donations. In addition, the availability of advanced products and sophisticated infrastructure will offer lucrative growth opportunities. Additionally, the presence of prominent players focused on securing the U.S. FDA approvals for advanced products will strengthen the North American industry demand potential.
For instance, in March 2023, The US government announced a plan Wednesday to overhaul the country’s organ transplant system. The US Department of Health and Human Services Health Resources and Services Administration said it will focus on accountability and transparency by seeking more contracts to operate the Organ Procurement and Transplantation Network and sharing data more transparently.
The system has only ever been managed by the nonprofit United Network for Organ Sharing, which has been recently criticised for its handling of organs, long waitlists for transplants and the number of deaths among people waiting: about 6,000 per year. There are currently more than 100,000 people in the United States waiting for an organ transplant.
COVID-19 Impact Analysis
With rising rates of COVID-19 at the end of 2021, there have been concerns about further limitations to organ donation and transplantation. The challenges in restarting transplant programs after suspensions in 2020 mean greater emphasis has been placed on maintaining activity.49 National transplantation authorities and societies have provided support and guidance to transplant centres to mitigate risk and ensure appropriate prioritization of transplantation.
Market Segmentation
By Product Type
• Portable
• Trolley
By Organ Type
• Kidney
• Heart
• Liver
• Lungs
• Others
By End-user
• Hospitals
• Ambulatory Surgical Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include TransMedics, Xvivo Perfusion AB, Paragonix Technologies Inc, OrganOx Limited, Bridge to Life Ltd, Institut Georges Lopez, Organ Recovery Systems among others.
Key Developments
 In September 2021, TransMedics Group, Inc. ("TransMedics"), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, stated that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its OCS Heart System for use with organs from donors after brain death (DBD).
Why Purchase the Report?
• To visualize the global organ care systems (OCS) market segmentation based on product type, organ type, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of organ care systems (OCS) market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global organ care systems (OCS) market report would provide approximately 69 tables, 70 figures and 183 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Organ Type
3.3. Snippet by End User
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the technological advancements in systems
4.1.1.2. Rising incidence of organ failures
4.1.2. Restraints
4.1.2.1. High cost associated with the systems
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Portable *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Trolley
8. By Organ Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Organ Type
8.1.2. Market Attractiveness Index, By Organ Type
8.2. Kidney *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Heart
8.4. Liver
8.5. Lungs
8.6. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ambulatory Surgical Centers
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Organ Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Organ Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Organ Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Organ Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.5.1. China
10.5.5.2. India
10.5.5.3. Japan
10.5.5.4. Australia
10.5.5.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Organ Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. TransMedics *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Xvivo Perfusion AB
12.3. Paragonix Technologies Inc
12.4. OrganOx Limited
12.5. Bridge to Life Ltd
12.6. Institut Georges Lopez
12.7. Organ Recovery Systems
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us